Payback? Analysts say Sarepta was blindsided by an FDA rejection driven by regulatory revenge
In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.
In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.